NeuroPace’s RNS For Epilepsy Becomes First FDA-Approved Responsive Neurostimulator
This article was originally published in The Gray Sheet
Executive Summary
While standard neurostimulators are open-loop systems that stimulate continuously or intermittently according to preprogramming, RNS is a more targeted, closed-loop system that monitors brain activity in real time and provides electrical stimulation to interrupt troubling patterns that might cause a seizure.
You may also be interested in...
NeuroPace Raises $67M To Help Commercialize RNS System For Epilepsy
The latest financing round will also support a new clinical trial of the RNS system for children with epilepsy.
Stanford Launches Trial Of NeuroPace’s Responsive Neuromodulation To Stop Overeating
The DBSLOC trial will study the feasibility of using NeuroPace’s RNS responsive neuromodulation system to stimulate the nucleus accumbens in order to stop “loss-of-control” eating in people with treatment-refractory obesity, especially those who have failed to respond adequately to gastric bypass surgery.
New Product Briefs
Product news from Cyberonics, TransEnterix Dexcom, Boston Scientific, St. Jude, Medtronic and Roche.